CHIMERIC NOROVIRUS P PARTICLE AND PREPARATION AND USE THEREOF

(19)

(11)

EP 3 323 885 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	05.05.2021 Bulletin 2021/18

(45)	Mention of the grant of the patent:
	24.03.2021 Bulletin 2021/12

(21)	Application number: 16823785.7

(22)	Date of filing: 29.06.2016

(51)

International Patent Classification (IPC):

C12N 7/04^(2006.01)
C12N 15/62^(2006.01)
A61K 39/385^(2006.01)
C12N 15/70^(2006.01)

C07K 19/00^(2006.01)
A61K 39/00^(2006.01)
A61P 25/28^(2006.01)
C12R 1/93^(2006.01)

(86)	International application number:
	PCT/CN2016/087643

(87)	International publication number:
	WO 2017/008638 (19.01.2017 Gazette 2017/03)

(54)	CHIMERIC NOROVIRUS P PARTICLE AND PREPARATION AND USE THEREOF CHIMÄRE NOROVIRUS-P-PARTIKEL UND HERSTELLUNG UND VERWENDUNG DAVON PARTICULE P DE NOROVIRUS CHIMÉRIQUE AINSI QUE SA PRÉPARATION ET SON UTILISATION

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

15.07.2015 CN 201510415556

(43)	Date of publication of application:
	23.05.2018 Bulletin 2018/21

(73)	Proprietors:
	Changchun Bcht Biotechnology Co. Jilin 130012 (CN) Jilin University Changchun, Jilin 130012 (CN)

(72)	Inventors:
	KONG, Wei Changchun Jilin 130012 (CN) WU, Hui Changchun Jilin 130012 (CN) JIANG, Chunlai Changchun Jilin 130012 (CN) YU, Xianghui Changchun Jilin 130012 (CN) FU, Lu Changchun Jilin 130012 (CN) LI, Yingnan Changchun Jilin 130012 (CN)

(74)	Representative: Gill Jennings & Every LLP
	The Broadgate Tower 20 Primrose Street London EC2A 2ES London EC2A 2ES (GB)

(56)

References cited: :

WO-A2-2006/112553
CN-A- 101 538 558

CN-A- 1 504 240
CN-A- 102 272 301

C. WIESSNER ET AL: "The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects", THE JOURNAL OF NEUROSCIENCE, vol. 31, no. 25, 22 June 2011 (2011-06-22) , pages 9323-9331, XP055541157, US ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.0293-11.2011
MING TAN ET AL: "Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus", NANOMEDICINE, vol. 7, no. 6, 1 June 2012 (2012-06-01), pages 889-897, XP055541116, GB ISSN: 1743-5889, DOI: 10.2217/nnm.12.62
LI YINGNAN ET AL: "Establishment of a novel method without sequence modification for developing NoV P particle-based chimeric vaccines", PROTEIN EXPRESSION AND PURIFICATION, vol. 121, 22 June 2011 (2011-06-22), pages 73-80, XP029465982, ISSN: 1046-5928, DOI: 10.1016/J.PEP.2016.01.003
LU FU ET AL: "Norovirus P particle-based active A[beta] immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease", SCIENTIFIC REPORTS, vol. 7, no. 1, 1 December 2017 (2017-12-01), XP055541106, DOI: 10.1038/srep41041
FU, LU ET AL.: 'Norovirus P particle: an Excellent Vaccine Platform for Antibody Production Against Alzheimer's Disease' IMMUNOLOGY LETTERS vol. 168, 05 September 2015, ISSN 0165-2478 pages 22 - 30, XP055344814
TAN, MING ET AL.: 'Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody Production' JOURNAL OF VIROLOGY vol. 85, no. 2, 31 January 2011, ISSN 0022-538X pages 753 - 764, XP002669772
FENG, GAIFENG ET AL.: 'Prokaryotic Expression and Immunogenicity of The Chimeric HBcAg Containing Abeta1-15' JOURNAL OF CENTRAL SOUTH UNIVERSITY (MEDICIAL SCIENCES) vol. 37, no. 3, 01 January 2012, pages 290 - 295, XP055509188 DOI: 10.3969/J.ISSN.1672-7347.2012.03.014

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).